Assessing Liver Function in Patients with HCC

Experts discuss the assessment of liver function in patients with hepatocellular carcinoma (HCC) while considering key data from recent clinical trials.

EP. 1: Risk Factors of Hepatocellular Carcinoma (HCC)

October 3rd 2023

Rachna Shroff, MD, MS, FASCO, discusses hepatocellular carcinoma, noting its rising global incidence and identifying underlying liver cirrhosis as a key risk factor influenced by conditions like viral hepatitis and fatty liver disease; diagnosis often involves radiographic imaging and triple-phase CT and MRI scans, while treatment necessitates a multidisciplinary approach involving hepatologists, surgeons, and other specialists.

EP. 2: Importance of Assessing Liver Function in HCC

October 3rd 2023

Drs Vogel and Singal discuss the critical importance of assessing liver function in hepatocellular carcinoma patients, as it impacts prognosis and treatment strategies; they mention the evolution from Child-Pugh scoring to the ALBI score, which uses albumin and bilirubin levels, for a more objective evaluation of liver health.

EP. 3: Assessing Liver Function in Patients With HCC: The ALBI Score

October 10th 2023

The ALBI score, originally developed to stratify cirrhotic patients undergoing resection, has evolved into a vital tool for assessing prognosis and treatment efficacy in various stages of hepatocellular carcinoma and is now being explored for its utility in other liver-related diseases.

EP. 4: Assessing Liver Function in Patients With HCC: The Child-Pugh Score

October 10th 2023

Arndt Vogel, MD, explains that the Child-Pugh score, although simpler to calculate than the ALBI score, sometimes lacks granularity in assessing liver function in hepatocellular carcinoma patients; however, both scoring systems are considered valuable tools in clinical settings and trials for evaluating liver function's prognostic impact on treatment outcomes.

EP. 5: Assessing Liver Function in Patients With HCC: The MELD Score

October 17th 2023

Rachna Shroff, MD, MS, FASCO, and Amit Singal, MD, discuss the use of various liver function assessment scores—Child-Pugh, ALBI, and MELD—in the care of patients with hepatocellular carcinoma, emphasizing their pros, cons, and roles in treatment decision-making.

EP. 6: Updates in First-Line Systemic Therapy for Patients With HCC

October 17th 2023

Arndt Vogel, MD, discusses the post-hoc analyses of two key clinical trials focusing on the impact of liver function, measured by ALBI and Child-Pugh scores, on outcomes in hepatocellular carcinoma treatments.

EP. 7: Key Outcomes Data in Patients With HCC Based on Liver Function

October 25th 2023

Amit Singal, MD, reviews analyses of the HIMALAYA and KEYNOTE-240 trials, focusing on the impact of liver function via ALBI grades on treatment outcomes and safety in patients with hepatocellular carcinoma.

EP. 8: Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

October 25th 2023

Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.

EP. 9: The Future of Liver Function Assessments in HCC

October 31st 2023

Experts emphasize the importance of using multiple liver function assessments for more comprehensive patient evaluation in hepatocellular carcinoma treatment.